GeNeuro announced that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health (FOPH) and that it will receive in this regard a grant of €6.4 million to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric ("neuropsychiatric") symptoms. Large-scale academic studies indicate that more than 10% of people infected with SARS-CoV-2 do not fully recover and/or develop new symptoms, with a high proportion of neurological and/or psychiatric disorders. With more than 265 million confirmed cases of COVID-19 worldwide, including more than 100 million in the US and Europe, this problem is now recognized as a major public health emergency, as it is affecting millions of people. A first publication in the Lancet EBioMedicine in April 2021 showed the systematic presence of the pathogenic protein W-ENV in hospitalized COVID-19 patients and its association with disease severity. Since then, GeNeuro has been involved in numerous academic efforts to understand the role of this. W-ENV protein, which is known to have a pro-inflammatory effect and pathogenicity on nervous system cells, in the syndromes suffered by COVID-19 patients, months after the infectious phase has ended.